GO:0140050 negative regulation of endocardial cushion to mesenchymal transition: Signaling Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140050 describes any process that stops, prevents, or reduces the frequency, rate, or extent of endocardial cushion to mesenchymal transition (EndoMT), a critical step in heart valve formation.
• Endocardial cushion to mesenchymal transition is the transformation of endocardial cells into invasive mesenchymal cells that populate the cushion tissue; negative regulation keeps this process temporally and spatially controlled.
• Key negative regulators include Muscleblind-like 1 (MBNL1), which suppresses TGF-beta-dependent EndoMT by inhibiting autocrine TGF-beta3 signaling.
• Hyaluronan and Wnt/beta-catenin signaling provide additional layers of negative control, ensuring proper valve primordium formation and morphogenesis.
• Dysregulation of negative regulation of EndoMT is linked to congenital heart valve defects such as bicuspid aortic valve and valve stenosis.
• CRISPR-based knockout, knock-in, and overexpression models are powerful tools to dissect the causal roles of candidate negative regulators in EndoMT.
Description
Endocardial cushion to mesenchymal transition (EndoMT) is a specialized form of epithelial-to-mesenchymal transition that occurs during heart development, where endocardial cells lining the atrioventricular canal and outflow tract delaminate, invade the underlying extracellular matrix, and form the mesenchymal cells of the endocardial cushions. These cushions subsequently remodel into the valves and septa of the mature heart. While much attention has focused on the positive drivers of EndoMT, such as TGF-beta and Notch signaling, the negative regulation of this process is equally critical for ensuring that the transition occurs with the correct timing, location, and magnitude. GO:0140050, negative regulation of endocardial cushion to mesenchymal transition, captures the biological processes that stop, prevent, or reduce the frequency, rate, or extent of EndoMT. Research into GO:0140050 has revealed that negative regulators act as molecular brakes, preventing excessive or ectopic mesenchymal transformation that could lead to malformed valves. For example, Muscleblind-like 1 (MBNL1) has been shown to be a negative regulator of TGF-beta-dependent epithelial-mesenchymal transition in atrioventricular canal endocardial cells, and its loss promotes invasive mesenchyme formation by stimulating autocrine TGF-beta3. Similarly, hyaluronan and Wnt/beta-catenin signaling have been implicated in restricting EndoMT to appropriate regions and developmental windows. Understanding these negative regulatory mechanisms is essential for deciphering the etiology of congenital heart valve diseases and for developing regenerative strategies. This article provides a comprehensive overview of GO:0140050, integrating authoritative QuickGO annotation data with real PubMed literature. We cover the definition, key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods, including CRISPR-based models, to support researchers studying this critical developmental process.
negative regulation of endocardial cushion to mesenchymal transition At A Glance
| GO ID | GO:0140050 |
|---|---|
| GO term | negative regulation of endocardial cushion to mesenchymal transition |
| Ontology | biological_process |
| Synonym | none |
| Major function | Suppression of the frequency, rate, or extent of endocardial cushion to mesenchymal transition during heart development |
| Related process | Endocardial cushion to mesenchymal transition (positive regulation); epithelial-to-mesenchymal transition |
| Key regulators | MBNL1, TGF-beta3, hyaluronan, Wnt/beta-catenin, Notch, VEGF |
| Disease relevance | Congenital heart valve defects, bicuspid aortic valve, valve stenosis |
| Research methods | CRISPR knockout/knock-in, RNA-seq, imaging, organ culture, transgenic models |
What Is GO:0140050?
GO:0140050, negative regulation of endocardial cushion to mesenchymal transition, is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of endocardial cushion to mesenchymal transition. In simpler terms, it encompasses all molecular and cellular events that put the brakes on the transformation of endocardial cells into mesenchymal cells during heart valve formation. This includes signaling pathways, transcriptional repressors, and extracellular matrix components that limit the extent of EndoMT, ensuring proper cushion development and preventing excessive or misplaced mesenchymal invasion.
Why Is negative regulation of endocardial cushion to mesenchymal transition Important in Cell Biology?
GO:0140050 is critically important because the negative regulation of endocardial cushion to mesenchymal transition ensures that heart valve development proceeds correctly. Without proper negative regulation, EndoMT can become excessive or occur in inappropriate locations, leading to malformed valves, stenosis, or regurgitation. Understanding these inhibitory mechanisms provides insights into congenital heart disease pathogenesis and may inform strategies for valve repair or regeneration.
• Prevents excessive mesenchymal cell invasion that could distort valve architecture.
• Ensures temporal and spatial restriction of EndoMT to the atrioventricular canal and outflow tract.
• Loss of negative regulators like MBNL1 leads to invasive mesenchyme formation and abnormal valve development.
• Dysregulation is associated with congenital heart valve defects such as bicuspid aortic valve.
• Provides potential therapeutic targets for modulating EndoMT in valve disease and regeneration.
• Helps explain how signaling pathways like TGF-beta, Wnt, and Notch are balanced during valvulogenesis.
• Offers a paradigm for studying negative regulation in other EMT contexts, including cancer.
• Guides the design of CRISPR screens to identify novel negative regulators of EndoMT.
• Informs tissue engineering approaches for heart valve replacement.
• Enhances our understanding of evolutionary conservation in heart development.
What Happens During negative regulation of endocardial cushion to mesenchymal transition?
Initiation of EndoMT and the Need for Brakes
In simple terms: EndoMT starts when endocardial cells receive signals to transform and invade, but this must be tightly controlled.
Endocardial cushion to mesenchymal transition is triggered by signals from the myocardium, including TGF-beta, Notch, and Wnt pathways. Endocardial cells delaminate, lose cell-cell adhesions, and migrate into the cushion matrix. Negative regulation begins concurrently to prevent excessive transformation. For instance, MBNL1 acts as a negative regulator by suppressing TGF-beta-dependent EMT in atrioventricular canal endocardial cells. Without such brakes, the process could run unchecked, leading to hypercellular cushions and valve malformations.
Molecular Suppression of TGF-beta Signaling
In simple terms: Certain proteins block the TGF-beta signals that drive EndoMT.
TGF-beta signaling is a major driver of EndoMT, and its negative regulation is crucial. MBNL1 has been shown to inhibit autocrine TGF-beta3 signaling, thereby reducing invasive mesenchyme formation. Loss of MBNL1 leads to increased TGF-beta3 expression and enhanced EndoMT, demonstrating its role as a negative regulator. This suppression likely involves post-transcriptional regulation of TGF-beta pathway components, as MBNL1 is an RNA-binding protein.
Role of Hyaluronan and Extracellular Matrix
In simple terms: The matrix around cells can send stop signals for EndoMT.
Hyaluronan, a major component of the extracellular matrix, is a critical regulator of endothelial-to-mesenchymal transition during cardiac valve formation. It can modulate signaling pathways and cell behavior. While hyaluronan is generally promigratory, its synthesis and degradation are tightly regulated to ensure proper EndoMT. Negative regulation may involve specific hyaluronan-binding proteins or fragments that inhibit transition. The balance of hyaluronan is essential for normal cushion development.
Wnt/beta-catenin and Notch Signaling Crosstalk
In simple terms: Wnt and Notch pathways interact to control when and where EndoMT stops.
Wnt/beta-catenin signaling enables developmental transitions during valvulogenesis, and its precise regulation is critical. Notch signaling also plays a sequential role in valve primordium formation and morphogenesis. Negative regulation of EndoMT may involve inhibition of Wnt or Notch at specific stages. For example, Wnt/beta-catenin activity must be downregulated for proper valve remodeling, and persistent activation can lead to valve defects. Similarly, Notch signaling is tightly controlled to prevent excessive EndoMT.
VEGF Signaling as a Modulator
In simple terms: VEGF can act as a stop signal depending on the context.
VEGF signaling has distinct spatiotemporal roles during heart valve development. In some contexts, VEGF inhibits EndoMT, acting as a negative regulator. For instance, VEGF treatment of endocardial cushions can reduce mesenchymal cell formation. The precise role depends on the developmental stage and location, highlighting the complexity of negative regulation.
Key Genes Involved in GO:0140050 negative regulation of endocardial cushion to mesenchymal transition
The following genes and proteins have been experimentally implicated in the negative regulation of endocardial cushion to mesenchymal transition, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MBNL1 | Negative regulator of TGF-beta-dependent EMT in atrioventricular canal endocardial cells; inhibits autocrine TGF-beta3 | Knockout leads to invasive mesenchyme; key model for studying negative regulation |
| TGFB3 | Pro-EMT ligand; its suppression by MBNL1 is critical for negative regulation | Target for CRISPR knockout to assess EndoMT |
| HAS2 | Hyaluronan synthase; hyaluronan is a critical regulator of EndoMT | Modulation affects cushion development |
| CTNNB1 | Beta-catenin; Wnt signaling enables developmental transitions; negative regulation may involve its inhibition | Knockout/knock-in to study Wnt role |
| NOTCH1 | Notch signaling regulates valve primordium formation; negative regulation may involve Notch inhibition | Conditional knockout models |
| VEGFA | VEGF signaling has distinct roles; can inhibit EndoMT in some contexts | Overexpression/knockdown studies |
| MEF2C | Transcription factor involved in heart development; may interact with negative regulators | Not directly cited but relevant; use with caution |
| GATA4 | Transcription factor essential for endocardial cushion formation; may be modulated by negative regulators | Not directly cited; use with caution |
| NFATC1 | Calcineurin/NFAT signaling regulates valve development; potential negative regulator | Not directly cited; use with caution |
| BMP2 | Pro-EMT signal; negative regulation may involve BMP antagonists | Not directly cited; use with caution |
| SNAI1 | EMT transcription factor; its suppression is part of negative regulation | Not directly cited; use with caution |
| SNAI2 | EMT transcription factor; its suppression is part of negative regulation | Not directly cited; use with caution |
| TWIST1 | EMT transcription factor; its suppression is part of negative regulation | Not directly cited; use with caution |
| CDH5 | VE-cadherin; loss promotes EndoMT; negative regulation may maintain its expression | Not directly cited; use with caution |
| ACTA2 | Smooth muscle actin; marker of mesenchymal transition; negative regulation reduces its expression | Not directly cited; use with caution |
| FN1 | Fibronectin; matrix component; negative regulation may limit its deposition | Not directly cited; use with caution |
| COL1A1 | Collagen; matrix component; negative regulation may limit its deposition | Not directly cited; use with caution |
How Is negative regulation of endocardial cushion to mesenchymal transition Regulated?
The negative regulation of endocardial cushion to mesenchymal transition is itself subject to regulation by various signaling pathways and transcription factors. For example, MBNL1 expression and activity may be modulated by developmental cues, and its RNA-binding activity is regulated by phosphorylation. Hyaluronan synthesis and degradation are controlled by enzymes like HAS2 and HYAL1, which in turn are regulated by growth factors and cytokines. Wnt/beta-catenin signaling is modulated by secreted antagonists such as DKK1 and SFRP proteins, which can inhibit EndoMT. Notch signaling is regulated by ligands like DLL4 and JAG1, and its negative regulation may involve feedback loops. VEGF signaling is modulated by soluble receptors and co-receptors, affecting its inhibitory role. Thus, a complex network of regulators ensures that EndoMT is appropriately restrained.
negative regulation of endocardial cushion to mesenchymal transition and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MBNL1 | Congenital heart valve defects; cancer EMT | Mbnl1 knockout mouse; CRISPR knockout in cell lines |
| TGFB3 | Valve disease; fibrosis | Tgfb3 knockout or overexpression in endocardial cells |
| HAS2 | Valve defects; hyaluronan-related disorders | Has2 conditional knockout mouse |
| CTNNB1 | Valve disease; Wnt signaling dysregulation | Beta-catenin gain/loss-of-function models |
| NOTCH1 | Bicuspid aortic valve; valve calcification | Notch1 knockout mouse; CRISPR in human cells |
Congenital Heart Valve Defects
Dysregulation of negative regulation of EndoMT is directly linked to congenital heart valve defects. Loss of MBNL1 in mice leads to abnormal heart valve development, including thickened and malformed valves, due to excessive EndoMT. Similarly, perturbations in hyaluronan or Wnt signaling result in valve anomalies. These findings suggest that mutations or polymorphisms in negative regulators could predispose humans to conditions such as bicuspid aortic valve or valve stenosis.
Bicuspid Aortic Valve and Valve Stenosis
Bicuspid aortic valve (BAV) is the most common congenital heart defect, often associated with altered EndoMT. Notch signaling, which is subject to negative regulation, is mutated in some BAV cases. Excessive EndoMT due to loss of negative regulators may contribute to valve thickening and stenosis. Understanding GO:0140050 could reveal new therapeutic targets for preventing valve degeneration.
Cancer and Fibrosis
While GO:0140050 is specific to heart development, the concept of negative regulation of EMT is relevant to cancer and fibrosis. MBNL1, a key negative regulator in EndoMT, is also implicated in cancer progression, where its loss promotes EMT and metastasis. Thus, insights from cardiac EndoMT may inform cancer biology, and vice versa.
From negative regulation of endocardial cushion to mesenchymal transition-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate EndoMT? | CRISPR knockout in endocardial cell lines or mouse models |
| What is the effect of a point mutation in gene X on EndoMT? | CRISPR point mutation knock-in in zebrafish or mouse |
| How does overexpression of gene X affect EndoMT? | CRISPR activation or transgenic overexpression |
| Where and when is gene X expressed during valve development? | Tagged knock-in reporter (e.g., GFP) |
| What are the downstream targets of gene X? | RNA-seq after knockout/overexpression |
| Can we identify novel negative regulators? | CRISPR library screening in EndoMT models |
How to Study the negative regulation of endocardial cushion to mesenchymal transition Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify downstream targets of negative regulators |
| CRISPR knockout | Loss-of-function effects | Test if a gene negatively regulates EndoMT |
| CRISPR knock-in | Precise mutation or tagging | Study point mutations or track protein localization |
| Overexpression | Gain-of-function effects | Assess if a gene inhibits EndoMT |
| Immunofluorescence | Protein localization and expression | Visualize mesenchymal markers in cushions |
| In situ hybridization | mRNA localization | Detect gene expression patterns during development |
| Organ culture | Ex vivo EndoMT | Test treatments on cushion explants |
| Flow cytometry | Cell surface markers | Quantify mesenchymal cells after EndoMT |
Transcriptomic Profiling (RNA-seq)
RNA sequencing allows global assessment of gene expression changes upon manipulation of negative regulators. For example, RNA-seq of MBNL1 knockout endocardial cells revealed upregulation of TGF-beta3 and other EMT markers. This method identifies downstream effectors and pathways controlled by negative regulators.
Imaging and Lineage Tracing
Confocal imaging of endocardial cushion explants or whole-mount embryos can visualize mesenchymal cell invasion. Lineage tracing using Tie2-Cre or Nfatc1-Cre labels endocardial cells and their derivatives, allowing quantification of EndoMT in vivo. Time-lapse imaging captures dynamic changes.
CRISPR Screening
Pooled CRISPR knockout screens in cell models of EndoMT can identify novel negative regulators. For instance, a screen for genes whose loss increases mesenchymal markers could uncover new brakes on EndoMT. This unbiased approach complements candidate-based studies.
Protein Interaction and Signaling Assays
Co-immunoprecipitation, Western blotting, and luciferase reporter assays can dissect signaling pathways. For example, MBNL1's interaction with TGF-beta3 mRNA can be studied by RNA immunoprecipitation. These methods reveal molecular mechanisms of negative regulation.
How CRISPR Can Be Used to Study GO:0140050 negative regulation of endocardial cushion to mesenchymal transition
Knockout
CRISPR knockout of candidate negative regulators such as MBNL1 in endocardial cells or mouse models can test their role in EndoMT. Mbnl1 knockout mice exhibit increased EndoMT and abnormal valve development, confirming its negative regulatory function. Knockout studies are essential for establishing causality.
Point Mutation
CRISPR point mutation knock-in can model specific human variants in negative regulator genes. For example, introducing a missense mutation in NOTCH1 identified in BAV patients into cell lines or mice can reveal its impact on EndoMT. This approach links genetic variants to functional outcomes.
Knock-in
Tagged knock-in of negative regulators (e.g., GFP or HA tags) allows visualization and purification of the protein. Knock-in of reporter genes under the control of endogenous promoters can track expression during valve development. This helps understand spatiotemporal dynamics.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression can elevate levels of negative regulators to test if they suppress EndoMT. Overexpression of MBNL1 in endocardial cells reduces TGF-beta3 and invasive mesenchyme. This gain-of-function approach complements loss-of-function studies.
How EDITGENE Supports negative regulation of endocardial cushion to mesenchymal transition Research
Researchers studying negative regulation of endocardial cushion to mesenchymal transition-related genes often need to determine whether a candidate gene is causally involved in suppressing EndoMT. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout and point mutation models to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of endocardial cushion to mesenchymal transition research.
Frequently Asked Questions About negative regulation of endocardial cushion to mesenchymal transition
What is GO:0140050?
GO:0140050 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of endocardial cushion to mesenchymal transition, a key step in heart valve formation.
What genes are involved in negative regulation of endocardial cushion to mesenchymal transition?
Key genes include MBNL1, which suppresses TGF-beta-dependent EMT, as well as components of hyaluronan, Wnt/beta-catenin, Notch, and VEGF signaling pathways.
How does MBNL1 negatively regulate EndoMT?
MBNL1 inhibits autocrine TGF-beta3 signaling, thereby reducing invasive mesenchyme formation in the atrioventricular canal.
What diseases are associated with dysregulation of this process?
Dysregulation is linked to congenital heart valve defects, including bicuspid aortic valve and valve stenosis.
What research methods are used to study negative regulation of EndoMT?
Common methods include CRISPR knockout/knock-in, RNA-seq, imaging, organ culture, and CRISPR library screening.
Can CRISPR be used to study this process?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of candidate genes in EndoMT.
What is the role of hyaluronan in EndoMT?
Hyaluronan is a critical regulator of endothelial-to-mesenchymal transition during cardiac valve formation, and its synthesis and degradation are tightly controlled.
How does Wnt signaling affect EndoMT?
Wnt/beta-catenin signaling enables developmental transitions during valvulogenesis, and its precise regulation is essential for proper valve formation.
What is the significance of Notch signaling in valve development?
Notch signaling regulates valve primordium formation and morphogenesis, and its negative regulation helps prevent excessive EndoMT.
How can EDITGENE help my research on this topic?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study negative regulators of EndoMT.
Conclusion
GO:0140050, negative regulation of endocardial cushion to mesenchymal transition, is a critical biological process that ensures proper heart valve development by restraining the transformation of endocardial cells into mesenchymal cells. Key negative regulators such as MBNL1, along with hyaluronan, Wnt, Notch, and VEGF signaling, provide essential brakes on EndoMT. Dysregulation of these mechanisms leads to congenital heart valve defects, highlighting their clinical importance. Advances in CRISPR-based models and high-throughput screening are accelerating the discovery of new negative regulators and their mechanisms, offering hope for novel therapeutic strategies.
References
- 1. Lagendijk AK et al.. 2013. Hyaluronan: a critical regulator of endothelial-to-mesenchymal transition during cardiac valve formation.. Trends Cardiovasc Med 23(5):135-42 PMID: 23295082
- 2. Vajda NA et al.. 2009. Muscleblind-like 1 is a negative regulator of TGF-beta-dependent epithelial-mesenchymal transition of atrioventricular canal endocardial cells.. Dev Dyn 238(12):3266-72 PMID: 19890912
- 3. Bosada FM et al.. 2016. Wnt/β-catenin signaling enables developmental transitions during valvulogenesis.. Development 143(6):1041-54 PMID: 26893350
- 4. Coram RJ et al.. 2015. Muscleblind-like 1 is required for normal heart valve development in vivo.. BMC Dev Biol 15:36 PMID: 26472242
- 5. MacGrogan D et al.. 2016. Sequential Ligand-Dependent Notch Signaling Activation Regulates Valve Primordium Formation and Morphogenesis.. Circ Res 118(10):1480-97 PMID: 27056911
- 6. Stankunas K et al.. 2010. VEGF signaling has distinct spatiotemporal roles during heart valve development.. Dev Biol 347(2):325-36 PMID: 20816797
- 7. LeMasters KE et al.. 2012. Loss of muscleblind-like 1 promotes invasive mesenchyme formation in endocardial cushions by stimulating autocrine TGFβ3.. BMC Dev Biol 12:22 PMID: 22866814
